Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Arthritis Research & Therapy
Philip MeaseArthur Kavanaugh

Abstract

In the GO-VIBRANT trial of intravenous golimumab in psoriatic arthritis (PsA), golimumab significantly inhibited radiographic progression. In post hoc analyses, we evaluated changes in total PsA-modified Sharp/van der Heijde scores (SHS) across levels of composite index-defined disease activity following treatment. In this phase-3, double-blind, placebo-controlled trial, 480 bio-naïve patients with active PsA randomly received intravenous golimumab 2 mg/kg (N = 241; week 0, week 4, every 8 weeks [q8w]) or placebo (N = 239; week 0, week 4, week 12, week 20) followed by golimumab (week 24, week 28, q8w) through week 52. Week 24 and week 52 SHS changes in patient subgroups, defined by levels of disease activity as assessed by several composite measures (minimal disease activity [MDA], very low disease activity [VLDA], Psoriatic ArthritiS Disease Activity Score [PASDAS], Disease Activity in Psoriatic Arthritis [DAPsA], Clinical Disease Activity Index [CDAI]), were evaluated post hoc in 474 patients with evaluable radiographic data. Partially (last-observation-carried-forward methodology) and completely (nonresponder methodology) missing data were imputed. Across indices, golimumab-treated patients demonstrated less radiographic pro...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Feb 1, 1980·Arthritis and Rheumatism·J F FriesH R Holman
Jul 28, 2006·Arthritis and Rheumatism·William TaylorUNKNOWN CASPAR Study Group
Aug 7, 2007·Best Practice & Research. Clinical Rheumatology·Daniel Aletaha, Josef S Smolen
Jul 3, 2008·Annals of the Rheumatic Diseases·J S SmolenUNKNOWN Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) S
Jan 17, 2009·Annals of the Rheumatic Diseases·L C CoatesP S Helliwell
Feb 24, 2009·Arthritis Research & Therapy·Georg Schett
Jul 17, 2012·Annals of the Rheumatic Diseases·Philip S HelliwellJessica A Walsh
Jul 3, 2013·The Journal of Rheumatology·Dafna D GladmanVinod Chandran
Sep 6, 2013·Immunological Investigations·Pedro P C Souza, Ulf H Lerner
May 17, 2014·Statistics in Medicine·Abdul J SankohRalph B D'Agostino
Aug 14, 2015·Annals of the Rheumatic Diseases·Monika M SchoelsJosef S Smolen
Dec 17, 2015·The Journal of Rheumatology·Laura C Coates, Philip S Helliwell
Apr 14, 2019·Arthritis Care & Research·M Elaine HusniElizabeth C Hsia

❮ Previous
Next ❯

Methods Mentioned

BETA
MDA

Software Mentioned

OMERACT
VIBRANT
GRAPPA
GO

Related Concepts

Related Feeds

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.

© 2021 Meta ULC. All rights reserved